BioNTech, China's Fosun strikes deal to potentially supply 10 mln doses of COVID-19 vaccine
Aug 27 (Reuters) - German drug developer BioNTech SE 22UAy.F on Thursday announced a potential deal with Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS to supply 10 million doses of their COVID-19 vaccine candidate to Hong Kong and Macau.
The two companies are also working jointly on the development and marketing of potential COVID-19 vaccine products based on BioNTech's mRNA technology platform in Mainland China, Hong Kong and Macau.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)
((manojna.kalyani@thomsonreuters.com; +91 8061822700;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
